Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3, Multicenter, Double-blind, Randomized, Non-inferiority Clinical Trial of Dapaconazole Cream 2% (Biolab Sanus Farmacêutica Ltda.) Versus Ketoconazole Cream 2% (Nizoral®, Janssen-Cilag Farmacêutica Ltda.) in Patients With Tinea Pedis

Trial Profile

Phase 3, Multicenter, Double-blind, Randomized, Non-inferiority Clinical Trial of Dapaconazole Cream 2% (Biolab Sanus Farmacêutica Ltda.) Versus Ketoconazole Cream 2% (Nizoral®, Janssen-Cilag Farmacêutica Ltda.) in Patients With Tinea Pedis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Jan 2019

At a glance

  • Drugs Dapaconazole (Primary) ; Ketoconazole
  • Indications Tinea pedis
  • Focus Registrational; Therapeutic Use
  • Sponsors Biolab Sanus Farmaceutica
  • Most Recent Events

    • 15 Jan 2019 Planned End Date changed from 1 Feb 2019 to 1 Nov 2019.
    • 15 Jan 2019 Planned primary completion date changed from 1 Aug 2018 to 1 Nov 2019.
    • 04 Jun 2018 Planned End Date changed from 1 Oct 2018 to 1 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top